Rituximab Biosimilar Prevents Poor Outcomes of Microscopic Polyangiitis and Granulomatosis with Polyangiitis as Effectively as Rituximab Originator
There has been no extensive study to compare the efficacy between rituximab originator (Mabthera®) and its biosimilar (Truxima®) for microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA). Here, we investigated the clinical effects of rituximab on poor outcomes of MPA and GPA in K...
Saved in:
Published in | Yonsei medical journal Vol. 61; no. 8; pp. 712 - 719 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
Yonsei University College of Medicine
01.08.2020
연세대학교의과대학 |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Be the first to leave a comment!